¸üÊÊÒËÓÃÈýÑõÁÆ·¨ÖÎÁƵIJ¡Ö¢
¸ù¾ÝÑ֤ҽѧ£¨EBM£©£¬¶ÔÈýÑõÖÎÁÆÃô¸ÐµÄ¼²²¡¿ÉÒÔ·ÖΪÈýÀà¡£Ö¤¾ÝÖÊÁ¿ÆÀ¹ÀÒÀ¾ÝÖ¤¾ÝÀ´Ô´ÀàÐÍ£¨À´×ÔËæ»úÁÙ´²ÊÔÑéµÄmeta·ÖÎöºÍϵͳÆÀ¼Û£©ÒÔ¼°ÆäËûÒòËØ£¬°üÀ¨Í³¼ÆÕæʵÐÔ¡¢ÁÙ´²Ïà¹ØÐÔ¡¢·ÑÓá¢Í¬ÐÐÆÀ¼ÛÈÏ¿É¡£
ÃÀ¹úÔ¤·À·þÎñ¹¤×÷×éºÍÅ£½òÑ֤ҽѧÖÐÐĸºÔðÖ¤¾ÝµÈ¼¶µÄÖƶ¨¡£ÈýÑõÁÆ·¨µÄÖ¤¾ÝËùÑ¡ÔñµÄ¼¶±ðΪ£º67,68
A¼¶Á¼ºÃµÄ¿Æѧ֤¾Ý±íÃ÷£¬ÈýÑõµÄÁÙ´²Òæ´¦´ó´ó³¬¹ýDZÔڵķçÏÕ¡£»ùÓÚËæ»ú¶ÔÕÕÊÔÑéµÄϵͳ»Ø¹Ë¡¢Í¬ÖÊÐÔ¶ÓÁÐÑо¿µÄϵͳÆÀ¼Û»òͬÖÖ²¡Àý¶ÔÕÕÑо¿µÄϵͳÆÀ¼Û¡£
B¼¶ÖÁÉÙ¹«Æ½µÄ¿Æѧ֤¾Ý±íÃ÷£¬ÈýÑõµÄÁÙ´²Òæ´¦´óÓÚDZÔڵķçÏÕ¡£»ùÓÚ¸öÌåËæ»ú¶ÔÕÕÊÔÑ飨ÖÃÐÅÇø¼äС£©¡¢¶ÓÁÐÑо¿»ò²¡Àý¶ÔÕÕÑо¿¡£
C¼¶ÖÁÉÙÓй«Æ½µÄ¿Æѧ֤¾Ý±íÃ÷£¬ÈýÑõÄܹ»ÌṩµÄÁÙ´²Òæ´¦£¬µ«ÀûÒæºÍ·çÏÕ²»ÏàÉÏÏ¡£»ùÓÚûÓÐÃ÷È·µÄÅúÅÐÐÔÆÀ¼ÛµÄר¼ÒÒâ¼û¡¢²¡Àý±¨¸æ£¬»ò»ùÓÚÉúÀíѧ¡¢ÊµÑéÊÒÑо¿£¬»ò¡°»ù±¾ÔÔò¡±£¬»òÃèÊöÐÔÁ÷Ðв¡Ñ§¡£
4.1A¼¶Ö¤¾ÝÏà¹Ø¼²²¡
¼¹Öù¼²²¡£¨×µ¼äÅÌÍ»³ö¡¢×µÌ廬ÍѼ°ÆäËû£¬µÈµÈ£©¡£69-72
Ïê¼û£ºISCO3£¨£©¡£ÈýÑõÔÚ·Ç·çʪÐÔÔ˶¯ÏµÍ³²¡±äÖеÄ×÷Óá£20
4.2B¼¶Ö¤¾ÝÏà¹Ø¼²²¡
ÕâЩ¼²²¡°üÀ¨£º
a.½ÃÕýÍâ¿Æ¼²²¡Óë¾Ö²¿¹Ç¹Ø½ÚÑס£
b.¹Ç÷À¼¡Èí×éÖ¯µÄÌÛÍ´
c.÷ƹÇÈí»¯Ö¢¡¢¹Ø½Ú²¡
d.¼¡ë첡£¨ÍøÇòÖâ¡¢÷ÆëìÑס¢Ï¥¹Ø½ÚÌÛÍ´ºÍ¼çÐäÐýתÐÔ¼¡ëìÑ×£©
e.èã¹Ç¾¥Í»ÏÁÕÐÔëìÇÊÑ×
f.Íó¹ÜÖ¢ºòȺ
g.ÌÇÄò²¡ºÍÌÇÄò²¡×ã
h.ÂýÐÔÆ£ÀÍ×ÛºÏÖ¢ºÍÏËά¼¡Í´
i.Í»·¢ÐԸоõÉñ¾ÐÔÌýÁ¦Ëðʧ73¡¢MeniereÊϲ¡(÷Äá¶ûÊÏ×ÛºÏÕ÷£©
j.ȱѪÐÔ¼²²¡ÍíÆÚ;ÏÂÖ«¶¯ÂöȱѪ
k.ÄêÁäÏà¹ØÐԻư߱äÐÔ£¨Î®ËõÐÍ£©¡£
l.È£³Ý²¡±ä£¨Ïê¼û¸½Â¼A£©
m.¹ÇËèÑס¢ÐØĤ·ÎÆøÖס¢ðü¹ÜŧÖס¢ÉË¿Ú¸ÐȾ¡¢Èì´¯¡¢ÂýÐÔÀ£Ññ¡¢ÌÇÄò²¡×ã¡¢ÉÕÉË¡£
n.²¡¶¾¡¢Ï¸¾ú¡¢Õæ¾úÒýÆðµÄ¼±ÐÔºÍÂýÐÔ¸ÐȾÐÔ¼²²¡£¬ÌرðÊÇÄÍ¿¹ÉúËØϸ¾úÒýÆðµÄ¼²²¡»ò½ÓÊÜ»¯Ñ§ÖÎÁÆÕߣ¬Èç¸ÎÑס¢°¬×̲¡¡¢ðåÕîºÍ´ø×´ðåÕî¸ÐȾ¡¢ÈéÍ·×´Áö²¡¶¾¸ÐȾ¡¢¼×Ñ¢ºÍÄîÖé¾ú²¡¡¢¼ÖµÚ³æ²¡ºÍÒþæß×ӳ没£»Bartolinitis£¨°ÍÊÏ£©ºÍÒõµÀÄîÖé¾ú²¡£»½ÅÆø£»¼×Ñ¢¡£
¾¡¹ÜÈýÑõÁÆ·¨ÊÇÖÎÁÆÕâЩ¼²²¡µÄÒ»¸öÓÐÓõÄÖ§³Ö£¬ÖµµÃÇ¿µ÷µÄÊÇ£¬ÎÞÂÛÊÇÈýÑõºÍËüµÄ´úл²úÎ°üÀ¨H2O2£¬¾ù²»Äܴﵽɱ¾ú¼ÁµÄ×é֯Ũ¶È£¬ÒòΪÕâЩÓÎÀëµÄ²¡ÔÌåÊܵ½Ñª½¬¿¹Ñõ»¯¼Á±£»¤£¬¶øϸ°ûÄڵIJ¡¶¾¸üÊÇÄÑÒÔʵÏֵġ£
Ö§³ÖÕâЩӦÓõÄÎÄÏ×ÔÚISCO3ÈýÑõÖÎÁƹú¼ÊͼÊé¹Ý¿ÉµÃµ½.16
4.3C¼¶Ö¤¾ÝÏà¹Ø¼²²¡
¸ù¾Ý³õ²½ÁÙ´²±¨¸æ£¬¶ÔÓÚÕâЩ¼²²¡£¬ÎÞÂÛÊÇ×÷ΪΨһµÄÖÎÁÆÐÎʽ»¹ÊÇ×÷ΪÌض¨ÖÎÁƵĸ¨ÖúÁÆ·¨£¬»ùÓÚÁÙ´²²¡Àý£¬ÈýÑõÁÆ·¨¶¼¾ßÓнϸߵÄÖÎÁƳɹ¦ÂÊ¡£
ÕâЩ¼²²¡°üÀ¨£º
a.°©Ö¢Ïà¹ØÐÔÆ£ÀÍ¡£ÈýÑõÖÎÁÆÁªºÏ´«Í³ÖÎÁÆ¿ÉÄÜ´Ù½øºÍ¸ÄÉÆÖ¢×´¡£È»¶ø£¬Æù½ñδÓÐÖ¤¾ÝÏÔʾÈýÑõÖÎÁƶ԰©Ö¢ÓÐÖÎÁÆЧ¹û¡£¶ÔÓÚËùÓÐÕâЩ¼²²¡£¬ÈýÑõÖÎÁÆÓ¦Óë³£¹æÖÎÁÆÏà½áºÏ£¬ÆäÓÐЧÐÔµÄÖ¤¾ÝÒÑ֤ʵ£¬µ«ÐèÒª¸ü¾«È·µÄÑо¿¡£
b.Ïø´
ÔÚÏÂÃæµÄ´«Í³ÁÆ·¨ºÍÈýÑõÁÆ·¨Ïà½áºÏ°¸ÀýÖУ¬ÖÁÉÙÓÐÀíÂÛÉϱíÃ÷¿ÉÄÜÊÇÓÐÒæµÄ£¬µ«Ã»ÓÐÕæÕýÒâÒåÉϵÄÁÙ´²Ö¤¾Ý¡£ÊµÀýÖ¤¾Ý±íÃ÷´æÔÚÖÎÁÆЧ¹û£¬µ«ÔÚÐí¶àÇé¿öÏ£¬ÁÆЧÊÇͨ¹ýʹÓò»Í¬ÀàÐ͵ÄÖÎÁÆ·½·¨´ïµ½µÄ£¬Òò´Ë½á¹ûÊDz»¿É¿¿µÄ¡£Ò»Ð©Ñо¿¶ÔÈýÑõÖÎÁÆÓëÁíÒ»ÖÖÖÎÁÆÏà½áºÏµÄÖÎÁƽøÐÐÁËÆÀ¹À£¬µÃ³öµÄ½áÂÛÊÇ£¬ÈýÑõÖÎÁÆÊÇ×÷Ϊ²¹³äÖÎÁƵĽÇÉ«¡£
a.×ÔÉíÃâÒßÐÔ¼²²¡£º¶à·¢ÐÔÓ²»¯Ö¢¡¢Àà·çʪÐԹؽÚÑס¢¿Ë¡²¡¡¢ÂýÐÔÑ×Ö¢ÐÔ³¦²¡¡£
b.·Î²¿¼²²¡£º·ÎÆøÖ×£¬ÂýÐÔ×èÈûÐԷμ²²¡£¬ÌØ·¢ÐÔ·ÎÏËά»¯ºÍ¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷¡£
c.Ƥ·ô²¡£ºÒøм²¡¡¢ÊªÕîºÍÌØÓ¦ÐÔƤÑס£
d.ŧ¶¾Ö¢£ºÑÏÖØŧ¶¾Ö¢ºÍ¶àÆ÷¹Ù¹¦ÄÜÕÏ°¡¢»µËÀÐÔ½îĤÑס¢¸¹Ä¤Ñס¢ÉÕÉË¡¢ÉÏò¢ñ¼¸ÐȾ¡¢»¯Å§ÐÔÖжúÑס¢±âÌÒÌåÑס¢¶îñ¼Ñס¢°òë×Ñס£
e.ºôÎüϵͳ¼²²¡£º·Î½áºË¡¢Ö§Æø¹ÜÑס¢ºôÎüË¥½ß¡¢±Çñ¼Ñס¢ÐØĤ·ÎÆøÖס£
f.賦¼²²¡£ºµ¨Ê¯Ö¢¡¢Ïû»¯ÐÔÀ£Ññ¡¢Ïû»¯µÀ³öѪ¡£
g.ÑÛ¿Æ£º¸ÉÑÛ×ÛºÏÕ÷¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±ä¡¢ÑÛÄÚÑס¢ÂöÂçĤ¼²²¡¡¢ÄêÁäÏà¹ØÐԻư߱äÐÔ¡¢ÊÓÍøĤɫËرäÐÔ¡¢ÂýÐÔÇà¹âÑÛ¡£
h.Éñ¾ÏµÍ³¼²²¡£º¾Æ¾«½ä¶Ï¡£
i.ÌÛÍ´£ºÏËά¼¡Í´¡¢õÅÍ´Ö¢¡¢Æ«Í·Í´¡£
j.ÈÑÉ̥Å̹¦Äܲ»È«¡¢ÏÈÕ××Óðï¡¢ÊäÂѹÜÕ³Á¬ÒýÆðµÄ²»ÔÐÖ¢¡£
k.Ѫ¹Ü¼²²¡£ºÈ±ÑªÐÔÐÄÔಡ¡£
l.°©×ªÒÆ£¨Èç×÷Ϊ¸¨ÖúÖÎÁÆ»ò¼õÉÙ»¯ÁÆ»ò·ÅÁƵĸ±×÷Óã©£ºÄÑÖÎÐÔ³öѪÐÔ·ÅÉäÐÔÖ±³¦Ñ×£»Ç°ÁÐÏÙÔöÉúÖ¢¡£
m.À×ŵÊÏ×ÛºÏÕ÷¡£
n.ÂýÐÔÉö¹¦ÄÜË¥½ß
o.¸Î²¡£º¼×¸Î¡¢ÒҸΡ¢±û¸Î
p.Ѫ¹ÜÐÔÏËά»¯ÐÔÄÔĤÑ×
q.¼××´ÏÙ½á½Ú
r.ÀÏÄêÐÔ³Õ´ô¡¢°¢¶û´Äº£Ä¬²¡
Ö§³ÖÕâЩӦÓõÄÎÄÏ×ÔÚISCO3ÈýÑõÖÎÁƹú¼ÊͼÊé¹Ý¿ÉµÃµ½.16
µÍ·¶Î§
ÉúÎïÔÙÉú
Í´·ç
ÏËά¼¡Í´
ÖÐ-µÍ·¶Î§
ÂýÐÔÉö¹¦ÄÜË¥½ß
°©Ö¢
Éö²¡
Öз¶Î§
Ö²ÎïÉñ¾ÏµÍ³¼²²¡£ºÀÏÄêÐÔ³Õ´ô¡¢ÅÁ½ðÉÖ¢¡¢³Õ´ô×ÛºÏÕ÷¡£
·Î²¿¼²²¡£º·ÎÆøÖס¢ÂýÐÔ×èÈûÐԷβ¡¡¢¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷¡£
ÑۿƼ²²¡£ºÊÓÍøĤɫËرäÐÔ¡¢°×ÄÚÕÏ¡¢Çà¹âÑÛ¡¢ÄêÁäÏà¹ØÐԻư߱äÐÔ¡£
ѪҺϵͳ¼²²¡£ºµØÖк£Æ¶ÑªB¡¢Á״ϸ°ûÐÔƶѪ¡£
Ѫ¹Ü¼²²¡£º¸ßѪѹ¡¢¾²Âö¹¦Äܲ»È«¡¢ÍâÖܶ¯Âö¼²²¡¡¢ÄÔѪ¹ÜÒâÍâ¡¢ÐÄÔಡ
ÖÐ-¸ß·¶Î§
²¡¶¾ÐÔ¼²²¡£ºµ¥´¿ðåÕ¶¾¸ÐȾ¡¢´ø×´ðåÕ¶¾¸ÐȾ¡¢°¬×̲¡¶¾¸ÐȾ/°¬×̲¡¡¢¼×Ð͸ÎÑס¢ÒÒÐ͸ÎÑס¢±ûÐ͸ÎÑס¢ÈéÍ·×´Áö²¡¶¾¸ÐȾ¡£
ÌÇÄò²¡
ÄÔ̱
Ƥ·ô²¡
½ÃÕýÍâ¿Æ¼²²¡
ÀæÐαÞë³æ²¡/¼ÖµÚ³æ²¡
ÄîÖé¾ú²¡¡¢Òþæß×ӳ没¡£
¹ýÃôÐÔ¼²²¡
ÂýÐÔÆ£ÀÍ×ÛºÏÕ÷
ϵͳÐÔºì°ßÀÇ´¯
Àà·çʪÐԹؽÚÑ×
¿Ë¡²¡
³¦µÀÑ×Ö¢ÐÔ¼²²¡
¶à·¢ÐÔÓ²»¯Ö¢0
ÔÎÄ
PATHOLOGIESMOREAPPROPRIATETOBETREATEDWITHOZONETHERAPY
Thediseasessensitivetotheozonetreatmentmaybeclassifiedintothreecategories,accordingtoEvidence-basedmedicine(EBM).Evidencequalitywasassessedbasedonthesourcetype(frommeta-analysesandsystematicreviewsofrandomizedclinicaltrials)aswellasotherfactorsincludingstatisticalvalidity,clinicalrelevance,currency,andpeer-reviewacceptance.
LevelsofevidencewereadaptedfromtheU.S.PreventiveServicesTaskForceandtheCentreforEvidenceBasedMedicine,Oxford.Selectedlevelsofevidenceinozonetherapywereclassifiedas:67,68
LevelA:Goodscientificevidencesuggeststhattheclinicalbenefitsofozonesubstantiallyoutweighthepotentialrisks.Basedonsystematicreviewswithrandomizedcontrolledtrials,systematicreviewswithhomogeneityofcohortstudiesorsystematicreviewswiththehomogeneityofcase-controlstudies.
LevelB:Atleastfairscientificevidencesuggeststhattheclinicalbenefitsofozoneoutweighthepotentialrisks.Basedonindividualrandomizedcontrolledtrials(withanarrowconfidenceinterval),cohortstudiesorcase-controlstudies.
LevelC.Atleastfairscientificevidencesuggeststhatthereareclinicalbenefitsprovidedbyozone,butthebalancebetweenbenefitsandrisksaretooclose.Basedonexpertopinionswithoutexplicitcriticalappraisals,casereports,orbasedonphysiology,benchresearch,or"firstprinciples",ordescriptiveepidemiology.
4.1DiseasesinthelevelA
Spinaldiseases(discherniation,spondylolysis,etc.).69-72
Fordetailssee:ISCO3().Ozoneinnon-rheumaticlo长春治白癜风最好的医院北京市白癜风
תÔØÇë×¢Ã÷£ºhttp://www.hxinad.net/klbzz/130.html
×îÐÂÎÄÕÂ
ÍƼöÎÄÕÂ
ÈȵãÎÄÕÂ